Treatment of Hepatitis C in Special Populations

Clinics in Liver Disease

Volumn 10, Issue 4, 2006, Pages 851-865

  Ramamurthy, Meera ^a   Muir, Andrew J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIRETROVIRUS AGENT; CONSENSUS INTERFERON; DIDANOSINE; GROWTH FACTOR; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ABSENCE OF SIDE EFFECTS; ACUTE PANCREATITIS; AFRICAN AMERICAN; ANEMIA; ASIAN; BRAIN HEMORRHAGE; CARDIOMYOPATHY; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG WITHDRAWAL; ETHNIC GROUP; HEMOLYSIS; HEPATITIS C; HEPATITIS C VIRUS; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; HYPOGLYCEMIA; KIDNEY FAILURE; LACTIC ACIDOSIS; LIVER DISEASE; LIVER TOXICITY; LUNG EDEMA; LYMPHOMA; MONOTHERAPY; NEUTROPENIA; RACE DIFFERENCE; REVIEW; SEIZURE; SIDE EFFECT; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

ADULT; AFRICAN AMERICANS; ANTIVIRAL AGENTS; ASIAN AMERICANS; HEPACIVIRUS; HEPATITIS C; HISPANIC AMERICANS; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2A; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN;

EID: 33845314448     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2006.08.001     Document Type: Review

References (75)

1. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep 47 (1998) 1-39
2. Alter M.J., Kruszon-Moran D., Nainan O.V., et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341 (1999) 556-562
3. Wiley T.E., Brown J., and Chan H. Hepatitis C infection in African Americans: its natural history and histological progression. Am J Gastroenterol 97 (2002) 700-706
4. Fleckenstein J. Chronic hepatitis C in African Americans and other minority groups. Curr Gastroenterol Rep 6 (2004) 66-70
5. Reddy K.R., Hoofnagle J.H., Tong M.J., et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 30 (1999) 787-793
6. McHutchison J.G., Poynard T., Pianko S., et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. Gastroenterology 119 (2000) 1317-1323
7. Bisceglie A.M., Sterling R.K., Chung R.T., et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol 43 (2005) 434-441
8. El-Serag H.B., Davila J.A., Peterson N.J., et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 139 (2003) 817-823
9. Crosse K., Umeadi O.G., Anania F.A., et al. Racial differences in liver inflammation and fibrosis related to chronic hepatitis C. Clin Gastroenterol Hepatol 2 (2004) 463-468
10. Sterling R.K., Stravitz R.T., Luketic V.A., et al. A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans. Clin Gastroenterol Hepatol 2 (2004) 469-473
11. Kinzie J.L., Naylor P.H., Nathani M.G., et al. African Americans with genotype I treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians. J Viral Hepat 8 (2001) 264-269
12. De Maria N., Colantoni A., Idilman R., et al. Impaired response to high-dose interferon treatment in African Americans with chronic hepatitis C. Hepatogastroenterology 49 (2002) 788-792
13. Muir A.J., Bornstein J.D., and Killenberg P.G. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 350 (2004) 2265-2271
14. Jeffers L.J., Cassidy W., Howell C.D., et al. Peginterferon alfa-2a and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 39 (2004) 1702-1708
15. Jacobson I., Brown R., and McCone J. Weight based ribavirin doing improves virologic response in HCV-infected genotype 1 African-Americans compared to flat dose ribavirin with peginterferon alfa2b combination therapy. Hepatology 40 (2004) 217A
16. Gross J.B. Double-dose peginterferon alfa-2b with weight-based ribavirin improves response for interferon/ribavirin non-responders with hepatitis C: final results of "RENEW". Hepatology 42 4, Suppl 1 (2005) 219A-220A
17. Conjeevaram H.S., Fried M.W., Jeffers L.J., et al. Peginterferon alfa-2a and ribavirin in African American and Caucasian patients with chronic hepatitis C genotype 1. Hepatology 42 4, Suppl 1 (2005) 275A-276A
18. Shiffman M.L. Treatment of chronic HCV in African Americans with genotypes 2 and 3. Gastroenterology 128 4, Suppl 2 (2005) A720
19. Sterling R.K., Hofmann R.N., Luketic V.A., et al. Treatment of chronic hepatitis C virus in Virginia Department of Corrections: can compliance overcome racial differences to response?. Am J Gastroenterol 99 (2004) 866-872
20. Shehab T.M., Fontana R.J., Oberhelman K., et al. Effectiveness of interferon alpha-2b and ribavirin combination therapy in the treatment of naive hepatitis C patients in clinical practice. Clin Gastroenterol Hepatol 2 (2004) 425-431
21. Kimball P., Elswick R.K., and Shiffman M. Ethnicity and cytokine production gauge response of patients with hepatitis C to interferon-alpha therapy. J Med Virol 65 (2001) 510-516
22. Sugimoto K., Stadanlick J., Ikeda F., et al. Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. Hepatology 37 (2003) 590-599
23. Layden-Almer J.E., Ribeiro R.M., Wiley T., et al. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 37 (2003) 1343-1350
24. Howell C., Dowling T., Jeffers L., et al. Peginterferon alfa-2A pharmacokinetics in African American and Caucasian Americans infected with HCV genotype 1. Hepatology 42 Suppl 1 (2005) 658A-659A
25. Layden-Almer J.E., Kuiken C., Ribeiro R.M., et al. Hepatitis C virus genotype 1a NS5A pretreatment sequence variation and viral kinetics in African American and white patients. J Infect Dis 192 (2005) 1078-1087
26. Ioannou G.N., Dominitz J.A., Weiss N.A., et al. Racial differences in the relationship between hepatitis C infection and iron stores. Hepatology 37 (2003) 795-801
27. Hare C.B., Morris J.A., Chu A., et al. Comparison of characteristics of treated and non-treated patients with Hepatitis C infection. Pharmacoepidemiol Drug Saf 15 (2006) 71-76
28. Alvarado-Esquivel C., Sablon E., Martinez-Garcia S., et al. Hepatitis virus and HIV infections in inmates of a state correctional facility in Mexico. Epidemiol Infect 133 4 (2005) 679-685
29. Celona A.F., Yu M.C., Prakash M., et al. Hepatitis C in a Los Angeles public hepatitis clinic: demographic and biochemical differences associated with race-ethnicity. Clin Gastroenterol Hepatol 2 6 (2004) 459-462
30. Bonacini M., Groshen M.D., Yu M.C., et al. Chronic hepatitis C in ethnic minority patients evaluated in Los Angeles County. Am J Gastroenterol 96 (2001) 2438-2441
31. Cheung R.C., Curie S., Shen H., et al. Chronic hepatitis C in Latinos: natural history, treatment eligibility, acceptance, and outcomes. Am J Gastroenterol 100 (2005) 2186-2193
32. Gaglio P.J., Rodriguez-Torres M., Herring R., et al., for the Infergen Study Group. Racial differences in response rates to consensus interferon in HCV infected patients naive to previous therapy. J Clin Gastroenterol 38 (2004) 599-604
33. Hepburn M.J., Hepburn L.M., Cantu N.S., et al. Differences in treatment outcome for hepatitis C among ethnic groups. Am J Med 117 (2004) 163-168
34. Chaudhuri S., Das S., Chowdhury A., et al. Molecular epidemiology of HCV infection among acute and chronic liver disease patients in Kolkata, India. J Clin Virol 32 (2005) 38-46
35. Hoang H., Kyulo N.L., Xia V., et al. Different clinical presentation and treatment response of chronic hepatitis C in Asian Americans versus non-Asian Americans. Hepatology 40 S1 (2005) 676A
36. Dev A., Sundararajan V., and Sievert W. Ethnic and cultural determinants influence risk assessment for hepatitis C acquisition. J Gastroenterol Hepatol 19 7 (2004) 792-798
37. D'Souza R., Sabin C.A., and Foster G.R. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol 100 7 (2005) 1509-1515
38. Nguyen M.H., Whittemore A.S., Garcia R.T., et al. Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis. Clin Gastroenterol Hepatol 2 9 (2004) 820
39. Dev A.T., McCaw R., Sundararajan V., et al. Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome. Hepatology 36 5 (2002) 1259-1265
40. Lee S.D., Yu M.L., Cheng P.N., et al. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. J Viral Hepat 12 3 (2005) 283-291
41. Missiha S.B. Impact of Asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C. Gastroenterology 128 4 Suppl. 2 (2005) A683-A684
42. Hoang H. Different clinical presentation and treatment response of chronic hepatitis C in Asian Americans versus non-Asian Americans. Hepatology 42 4 Suppl 1 (2005) 676A
43. Staples C.T., Rimland D., and Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta VA (Veterans Affairs) Medical Cohort Study (HAVACS): the effects of coinfection on survival. Clin Infect Dis 29 (1999) 150-154
44. Greub G., Lederberger B., Battegay M., et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 356 (2000) 1800-1805
45. Rumi M.G., Colombo M., Grigeri A, et al. High prevalence of antibody to hepatitis C virus in hemophiliacs with normal transaminase levels. Ann Intern Med 112 (1990) 379-397
46. Bica I., McGovern B., Dhar R., et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 32 (2001) 492-497
47. Sherman K., Rouster S., Chung R., et al. Hepatitis C virus prevalence among patients infected with HIV. Clin Infect Dis 34 (2002) 831-837
48. Allory Y., Charlotte F., Benhamou Y., et al. Impact of human immunodeficiency virus infection on the histological features of chronic hepatitis C: a case-control study. The MULTIVIRC group. Hum Pathol 31 (2000) 69-74
49. Zylberberg H., Benhamou Y., Lagneaux J.L., et al. Safety and efficacy of interferon-ribavirin therapy in HCV-HIV coinfected subjects. Gut 47 (2000) 694-697
50. Brau N., Rodriguez-Torres M., Prokupek D., et al. Treatment of chronic hepatitis C in HIV/HCV coinfection with interferon alpha-2b + full course vs. 16-week delayed ribavirin. Hepatology 39 (2004) 989-998
51. Torriani F.J., Rodriguez-Torres M., Rockstroh J.K., et al. Peginterferon alfa-2a plus ribavirin for chronic HCV infection in HIV-infected patients. N Engl J Med 351 (2004) 438-450
52. Chung R.T., Andersen J., Volberding P., et al. Peginterferon alfa-2a plus ribavirin vs. interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 351 (2004) 451-459
53. Carrat F., Bani-Sadr F., Stanislas P., et al. Pegylated interferon alfa-2b vs. standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 292 (2004) 2839-2848
54. Laguno M., Murillas J., Blanco J.L., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for HIV/HCV co-infected patients. AIDS 18 (2004) F27-F36
55. Vento S., Garofano T., Renzini C., et al. Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy. AIDS 12 (1998) 116-117
56. Rutschmann O.T., Negro F., Hirschel A., et al. Impact of treatment with human immunodeficiency virus protease inhibitors on hepatitis C viremia in patients coinfected HIV. J Infect Dis 177 (1998) 783-785
57. Niu M.T., Coleman P.J., and Alter M.J. Multicenter study of hepatitis C virus infection in chronic hemodialysis patients and hemodialysis center staff members. Am J Kidney Dis 22 (1993) 568-573
58. Fabrizi F., Martin P., Dixit V., et al. Quantitative assessment of HCV load in chronic hemodialysis patients: a cross-sectional survey. Nephron 80 (1998) 428-433
59. Sterling R.K., Sanyal A.J., Luketic V.A., et al. Chronic hepatitis C infection in patients with end stage renal disease: characterization of liver histology and viral load in patients awaiting transplantation. Am J Gastroenterol 94 (1999) 3576-3582
60. Cotler S.J., Diaz G., Gundlapalli S., et al. Characterization of hepatitis C in renal transplant candidates. J Clin Gastroenterol 35 (2002) 191-195
61. Stehman-Breen C.O., Emerson S., Gretch D., et al. Risk of death among chronic dialysis patients infected with hepatitis C virus. Am J Kidney Dis 32 (1998) 629-634
62. Nakayama E., Akiba T., Marumo F., and Sato C. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol 11 (2000) 1896-1902
63. Mathurin P., Mouquet C., Poynard T., et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 29 (1999) 257-263
64. Hanafusa T., Ichikawa Y., Yazawa K., et al. Hepatitis C virus infection in kidney transplantation and a pilot study of the effects of interferon-alpha therapy. Transplant Proc 30 (1998) 122-124
65. Fabrizi F., Martin P., Dixit V., et al. Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies. Am J Transplant 5 (2005) 2433-2440
66. Thervet E., Pol S., Legendre C., et al. Low-dose recombinant leukocyte interferon-alpha treatment of hepatitis C viral infection in renal transplant recipients: a pilot study. Transplantation 58 (1994) 625-628
67. Magone M., Holley J.L., Shapiro R., et al. Interferon-alpha-induced acute renal allograft rejection. Transplantation 59 (1995) 1068-1070
68. Tokumoto T., Tanabe K., Ishikawa N., et al. Effect of interferon-alfa treatment in renal transplant recipients with chronic hepatitis C. Transplant Proc 30 (1998) 3270-3272
69. Russo M.W., Goldsweig C.D., Jacobson I.M., et al. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol 98 7 (2003) 1610-1615
70. Meyers C.M., Seeff L.B., Stehman-Breen C.O., et al. Hepatitis C and renal disease: an update. Am J Kidney Dis 42 (2003) 631-657
71. Mousa D.H., Abdalla A.H., Al-Shoail G., et al. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplant Proc 36 (2004) 1831-1834
72. Bruchfeld A., Stahle L., Andersson J., et al. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection-a pilot study. J Viral Hep 8 (2001) 287-292
73. Tan A.C., Brouwer J.T., Glue P., et al. Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study. Nephrol Dial Transplant 16 (2001) 193-195
74. Russo M.W., Ghalib R., Sigal S.H., et al. A multi-center randomized trial of pegylated interferon alfa-2b monotherapy (Peg-Intron) in patients with chronic hepatitis C and end stage kidney disease on dialysis. Hepatology 40 (2004) 399A
75. Dienstag J.L., and McHutchison J.G. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology 130 (2006) 225-230